Evidence map›Paper›PMID 42893170›Full record

ReviewJournal of analytical methods in chemistry2026

Frontiers in Neurotransmitter Probes: Innovations and Perspectives in Norepinephrine Detection Technology.

Rufei Ma, Zhao Wang

Abstract readReview
In one paragraph

Review in Journal of analytical methods in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rufei MaSchool of Physical Education and International Equestrian Academy Wuhan Business University Wuhan 430056 China wbu.edu.cn.
Zhao WangSchool of Physical Education and International Equestrian Academy Wuhan Business University Wuhan 430056 China wbu.edu.cn.ORCID https://orcid.org/0000-0002-2687-0122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Norepinephrine (NE), the primary neurotransmitter of locus coeruleus projections, plays a crucial role in regulating arousal, emotion, memory, and stress responses. Its dysregulation is closely associated with various neurological disorders such as depression, Parkinson's disease, and epilepsy. However, conventional detection techniques such as microdialysis coupled with liquid chromatography are constrained by limited spatiotemporal resolution and inherent invasiveness, largely due to NE's low concentration, rapid metabolism, and complex distribution in vivo. These limitations make real-time, in situ dynamic monitoring particularly challenging. In recent years, fluorescence and bioluminescence probe technologies, founded on molecular recognition or self-assembly strategies, have enabled notable advances in the in situ detection and imaging of NE, owing to their superior spatiotemporal resolution, favorable biocompatibility, and versatile design. This review summarizes several representative studies in the field, covering probe design principles, response mechanisms, analytical performance, and biological applications. It also highlights emerging frontiers such as subcellular localization, in vivo dynamic imaging, millisecond-scale monitoring, multitarget cooperative recognition, and integrated diagnosis and therapy. These technologies have deepened our understanding of the spatiotemporal dynamics of NE in physiological and pathological processes, while also providing powerful tools for mechanistic research, early diagnosis, and precise treatment of neuropsychiatric disorders.

Indexed as

excited-state intramolecular proton transferferroptosisglutathionenear-infrared probestroke

Identifiers

PMID42893170
PMCPMC13676032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.